Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia

MT Newswires Live

Mar 31

Apollomics (APLM) and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.

The deal entitles Apollomics to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.

Apollomics will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.

Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.

Shares of Apollomics jumped 12% in recent trading.

Price: 8.29, Change: +0.89, Percent Change: +12.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523926011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523926011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2523926011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523926011","market":"sh","top_or_hot":-1,"title":"Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/APLMW\">Apollomics</a> (APLM) and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.</p><p>The deal entitles Apollomics to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.</p><p>Apollomics will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.</p><p>Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.</p><p>Shares of Apollomics jumped 12% in recent trading.</p><p>Price: 8.29, Change: +0.89, Percent Change: +12.03</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/APLMW\">Apollomics</a> (APLM) and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.</p><p>The deal entitles Apollomics to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.</p><p>Apollomics will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.</p><p>Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.</p><p>Shares of Apollomics jumped 12% in recent trading.</p><p>Price: 8.29, Change: +0.89, Percent Change: +12.03</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLMW","symbol_name":"Apollomics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523926011","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523926011","pubTimestamp":1743433853,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Apollomics  and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.The deal entitles Apollomics to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.Apollomics will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.Shares of Apollomics jumped 12% in recent trading.Price: 8.29, Change: +0.89, Percent Change: +12.03","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLMW":"Apollomics","APLM":"Apollomics Inc","BK4139":"生物科技"},"translate_title":"Apollomics签署Vebreltinib在亚洲的独家开发和商业化协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLM":0.9,"APLMW":1},"content_text":"Apollomics (APLM) and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.The deal entitles Apollomics to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.Apollomics will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.Shares of Apollomics jumped 12% in recent trading.Price: 8.29, Change: +0.89, Percent Change: +12.03","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}